<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30223">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065817</url>
  </required_header>
  <id_info>
    <org_study_id>13-004890</org_study_id>
    <nct_id>NCT02065817</nct_id>
  </id_info>
  <brief_title>Dose of Labeled Cholesterol for Kinetics: A Pilot Study</brief_title>
  <official_title>Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine the optimum time and dose to draw blood samples using a
      tracer for HDL kinetics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incorporation of orally administered 13C3 cholesterol into plasma cholesterol</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>13C3 cholesterol, which is labeled with a stable isotope, will be administered orally. Blood samples will be taken every 4-6 hours for 72 hours for the measurement of stable isotopic enrichment in cholesterol using gas chromatography-mass spectrometry. The study has a dual purpose: to determine the optimum oral dose of isotope, and to determine the time of peak enrichment in plasma cholesterol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lipid Metabolism</condition>
  <arm_group>
    <arm_group_label>Tracer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stable isotope of cholesterol</intervention_name>
    <arm_group_label>Tracer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Healthy men and women ages 18 - 50

        Exclusion Criteria:

          -  Cardiovascular disease

          -  Metabolic disease

          -  Hematologic disorder

          -  Liver or kidney disease

          -  phenylketonuria

          -  Currently taking lipid lowering medications or any other drugs that could affect
             lipid metabolism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Miles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Dunagan, RN</last_name>
      <phone>507-255-0111</phone>
      <email>dunagan.kelly@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Almira Smailovic, BS</last_name>
      <phone>5072557536</phone>
      <email>Smailovic.Almira@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M Miles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Miles</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lipid</keyword>
  <keyword>Apolipoproteins</keyword>
  <keyword>Cardiovascular disease risks</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
